Tambotatug clinical trials
How each study uses tambotatug is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the tambotatug studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
3 studies that test it; most in 2018 (1)
| Year | Studies |
|---|---|
| 2018 | 1 |
| 2022 | 1 |
| 2024 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 0
Shanghai Pharmaceuticals Holding Co., Ltd (2) · Shanghai Jiaolian Drug Research and Development Co., Ltd (1)
Often tested with
Tested in the same studies.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 2, 1 in phase 3
Studies that test tambotatug, phase 3 first.
- Oct 2027A Clinical Study of B001 Injection in the Treatment of Neuromyelitis Optica Spectrum Disorders(NMOSD)Phase 2/3 · Shanghai Jiaolian Drug Research and Development Co., Ltd
- Dec 2026Clinical Study of B001 Injection in Subjects With Neuromyelitis Optic Spectrum Disorder (NMOSD)Early Phase 1 · Shanghai Pharmaceuticals Holding Co., Ltd
Studies
Open first, then newest update. How each study uses tambotatug is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- A Clinical Study of B001 Injection in the Treatment of Neuromyelitis Optica Spectrum Disorders(NMOSD)RecruitingPhase 2/3Shanghai Jiaolian Drug Research and Development Co., LtdNCT06413654Written as B001
- Clinical Study of B001 Injection in Subjects With Neuromyelitis Optic Spectrum Disorder (NMOSD)RecruitingEarly Phase 1Shanghai Pharmaceuticals Holding Co., LtdNCT05145361Written as B001 injection
- B001 in Patients With CD20 Positive B-cell Non Hodgkin's LymphomaCompletedPhase 1Shanghai Pharmaceuticals Holding Co., LtdNCT03332121Written as B001
Codes
What other systems call tambotatug · ClinicalTrials.gg INT014715
- UNII (FDA) 3QM4S9TD7XTAMBOTATUGOne source FDA
- NCI Thesaurus C224793TambotatugOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 3QM4S9TD7X | TAMBOTATUG | One source FDA |
| NCI Thesaurus | C224793 | Tambotatug | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.